Login to Your Account



Zalicus Shifts Gears to Pain After Phase IIb Miss in RA

By Catherine Shaffer
Staff Writer

Tuesday, September 11, 2012
Zalicus Inc., of Cambridge, Mass., is immediately terminating its development program for Synavive after a Phase IIb trial in rheumatoid arthritis failed to show meaningful clinical benefit compared to prednisolone, the active glucocorticoid component of the drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription